Clinical Trial Update: Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab [Phase 2]

View source ↗

Summary

Clinical trial protocol update for previously untreated chronic lymphocytic leukemia using bendamustine and ofatumumab; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Nevada Cancer Institute | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: TERMINATED